‘Viagra for women’ will get third chance at FDA approval

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

WASHINGTON — The makers of a twice-rejected pill intended to boost libido in women will try once again this week to persuade regulators that the drug warrants approval as the first prescription treatment for low sexual desire in women.

But a new review released by the Food and Drug Administration shows government scientists still have concerns about whether the drug's benefits outweigh its risks. The FDA review highlights several safety issues with flibanserin, including low blood pressure and fainting spells. Those problems increased when patients combined the drug with alcohol.

A panel of FDA experts will discuss those and other issues at a public meeting Thursday, before voting on whether to recommend the drug's approval.

The ongoing saga of Sprout Pharmaceutical's much-debated drug illustrates the complex politics and science surrounding women's sexuality.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.